



AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference

February 17, 2023

MASON, Ohio--(BUSINESS WIRE)--Feb. 17, 2023-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference.

AtriCure's management is scheduled to present on Wednesday, March 15, 2023 at 8:00 am Eastern Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at <https://ir.atricure.com>.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator[®] Synergy[™] Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip[®] Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF[™] Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE[®] probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit [AtriCure.com](https://www.atricure.com) or follow us on Twitter [@AtriCure](https://twitter.com/AtriCure).



View source version on [businesswire.com](https://www.businesswire.com/news/home/20230217005005/en/): <https://www.businesswire.com/news/home/20230217005005/en/>

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Lynn Lewis or Marissa Bych
Gilmartin Group
Investor Relations
lynn@gilmartinir.com
marissa@gilmartinir.com

Source: AtriCure, Inc.